Publik
All sources

Directorate · Ministry of Health and Care Services

Norwegian Medical Products Agency

The Norwegian Medical Products Agency is the regulatory authority for medicines and medical devices.

Latest from Norwegian Medical Products Agency

  1. Public consultation

    Consultation on EU Regulation harmonizing quality management and conformity assessment procedures for medical devices in Norway

    • DMP proposes Norway to implement a new EU regulation setting rules on approval and control of medical devices.
    • The regulation sets maximum processing times for applications, requirements for pricing offers, and cost reporting.
    BusinessEULegislation
    + 7 more bullets in the app
  2. Report

    Nytt om legemidler no. 12 2026 covers seasonal influenza vaccines and changes in state vaccine supply

    • The issue came out on 13.10.2026. It has two items on changes: flu vaccines for the 2026/2027 season and changes to vaccines supplied by the state.
    • The available text is only a short overview. It does not say what is changing or who is affected. That is in the PDF issue.
    MedicinesPublic health
    Read the item in the app
  3. News article

    Ocrevus can cause liver injury – liver tests required before starting, and treatment to be stopped if it occurs

    • A review of the data shows that the medicine Ocrevus (ocrelizumab) can harm the liver. It is used for adults with multiple sclerosis (MS).
    • Most cases were mild to moderate, but some were serious or life-threatening.
    MedicinesPublic health
    + 4 more bullets in the app
  4. News article

    Norway's DMP seeks user feedback on new case-handling system for drug approvals introduced in 2025

    • In 2025, DMP launched a new digital system for handling applications to approve medicines in Norway. They now want to hear from companies and others who use the system, and are asking them to fill in a short survey.
    • The survey takes about five minutes, and the deadline to respond is 31 October 2026.
    DigitalisationMedicines
    Read the item in the app
  5. News article

    Norway's Medicines Agency (DMP) to hold industry information meeting on new EU pharmaceutical legislation on 15 December 2026

    • Norway's medicines regulator, DMP, is holding an information meeting on 15 December 2026, from 13:30 to 16:45, at its offices in Oslo.
    • The meeting targets people who work with medicine regulations, and will focus on new EU rules for pharmaceuticals, known as the New Pharma Legislation (NPL).
    EØSEUMedicines
    + 1 more bullet in the app
  6. Public consultation

    Proposed regulation would require pharmaceutical wholesalers to stockpile selected vaccines and immunoglobulins

    • Norway's medicines authority (DMP) has launched a public consultation on new rules for wholesalers that supply pharmacies with medicines.
    • Under the proposal, these wholesalers would be required to keep emergency stocks of certain vaccines and immunoglobulins (antibody-based medicines used for treatment or prevention) — a requirement that does not exist today.
    MedicinesPreparedness
    + 2 more bullets in the app
  7. News article

    Novo Nordisk withdraws insulin products, triggering rationing of Humulin NPH in Norway

    • Novo Nordisk is pulling some of its insulin products from the Norwegian market, which means supplies of Humulin NPH — a type of insulin for diabetes patients — will be limited and rationed.
    Medicines
    Read the item in the app
  8. News article

    Norway's DMP is assessing two products under the new EU joint clinical assessment system for medicines and medical devices

    • DMP is now reviewing two new medical products as part of a new European cooperation: a gene therapy for inherited hearing loss (lunsotogene parvec) and a heart-related medical device.
    • The first joint European assessment report was approved in 2026. Three reports are now complete, and 15 products are currently being assessed.
    EØSEUMedicines
    + 4 more bullets in the app
  9. News article

    Acute NPH-insulin shortage in Norway: up to 30,000 diabetes patients must switch treatment before 30 November 2026

    • Insulatard, an NPH-insulin used by up to 30,000 diabetes patients, will stop being sold in Norway on 30 November 2026 because the manufacturer is ending sales for business reasons.
    • The only other NPH-insulin available, Humulin, is so scarce it can only cover about one in ten patients who need it — so most people will have to switch to a different type of insulin.
    MedicinesPreparedness
    + 6 more bullets in the app
  10. News article

    Norway criminalises seven peptides and growth hormone secretagogues – including BPC-157 and ibutamoren – from 15 September 2026

    • From 15 September 2026, it is a criminal offence in Norway to produce, import, store or use seven named substances — BPC-157, CJC-1295, ipamorelin, TB-500, tesamorelin, sermorelin and ibutamoren. The penalty can be a fine or prison.
    • The substances were already banned for athletes under WADA rules. What is new is that the ban now covers everyone in Norway, giving customs and police stronger tools against criminal networks selling these products.
    DrugsMedicinesPublic health
    + 3 more bullets in the app

Follow Norwegian Medical Products Agency in Publik

  • We check Norwegian Medical Products Agency every 20 minutes, around the clock.
  • Every new item is boiled down to a summary of up to 12 clear bullets.
  • You get a push notification in the app the moment something new is published.
Follow the source in PublikFree to get started.
Norwegian Medical Products Agency online